Susquehanna Fundamental Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,000	Closed	-$1.42M	–	1824
2021 Q3	$1.42M	Buy	8,000 +5,600	+233%	+$901K	0.03%	726
2021 Q2	$388K	Sell	2,400 -1,700	-41%	-$273K	0.01%	1267
2021 Q1	$702K	Buy	4,100 +1,600	+64%	+$317K	0.01%	1020
2020 Q4	$549K	Hold	2,500	–	–	0.01%	1069
2020 Q3	$415K	Buy	2,500 +200	+9%	+$27.4K	0.01%	948
2020 Q2	$263K	Buy	+2,300	New	+$223K	0.01%	775

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Susquehanna Fundamental Investments's MRTX Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 8,000 shares — an estimated $1.42M sold.

Susquehanna Fundamental Investments first reported a position in MRTX in Q2 2020 and held it in 6 quarters. The position peaked at $1.42M in Q3 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Susquehanna Fundamental Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 8,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.42M.
Susquehanna Fundamental Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Susquehanna Fundamental Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $1.42M in Q3 2021.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.